Federated Hermes’s GSK GSK Stock Holding History

Federated Hermes’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.33M	Sell	169,014 -2,674,401	-94%	-$145M	0.02%	658
2025 Q4	$139M	Sell	2,843,415 -793,572	-22%	-$37M	0.23%	109
2025 Q3	$157M	Buy	3,636,987 +4,516	+0.1%	+$176K	0.28%	89
2025 Q2	$139M	Buy	3,632,471 +3,494,657	+2,536%	+$134M	0.26%	100
2025 Q1	$5.34M	Buy	137,814 +46,715	+51%	+$1.71M	0.01%	702
2024 Q4	$3.08M	Sell	91,099 -17,662	-16%	-$636K	0.01%	841
2024 Q3	$4.45M	Buy	108,761 +716	+0.7%	+$29.3K	0.01%	742
2024 Q2	$4.16M	Sell	108,045 -94,223	-47%	-$3.96M	0.01%	754
2024 Q1	$8.67M	Sell	202,268 -11,180	-5%	-$461K	0.02%	596
2023 Q4	$7.91M	Sell	213,448 -5,939	-3%	-$213K	0.02%	610
2023 Q3	$7.95M	Buy	219,387 +85,699	+64%	+$3.04M	0.02%	588
2023 Q2	$4.76M	Buy	+133,688	New	+$4.8M	0.01%	712
2022 Q2	–	Sell	-98,958	Closed	-$5.39M	–	2207
2022 Q1	$5.39M	Buy	+98,958	New	+$5.38M	0.01%	762
2020 Q4	–	Sell	-1,801,842	Closed	-$84.8M	–	2272
2020 Q3	$84.8M	Sell	1,801,842 -422,744	-19%	-$21.2M	0.2%	124
2020 Q2	$113M	Sell	2,224,586 -487,939	-18%	-$25M	0.28%	77
2020 Q1	$128M	Sell	2,712,525 -419,029	-13%	-$22.4M	0.38%	50
2019 Q4	$184M	Buy	3,131,554 +14,220	+0.5%	+$791K	0.41%	43
2019 Q3	$166M	Sell	3,117,334 -29,067	-0.9%	-$1.5M	0.41%	45
2019 Q2	$157M	Sell	3,146,401 -3,999	-0.1%	-$201K	0.38%	47
2019 Q1	$165M	Sell	3,150,400 -67,376	-2%	-$3.37M	0.41%	43
2018 Q4	$154M	Buy	3,217,776 +1,700	+0.1%	+$83.7K	0.42%	43
2018 Q3	$161M	Sell	3,216,076 -276,864	-8%	-$14.1M	0.38%	53
2018 Q2	$176M	Buy	3,492,940 +59,185	+2%	+$2.98M	0.52%	34
2018 Q1	$168M	Sell	3,433,755 -592,532	-15%	-$27.6M	0.49%	38
2017 Q4	$179M	Sell	4,026,287 -353,782	-8%	-$16.3M	0.5%	39
2017 Q3	$222M	Buy	4,380,069 +771,145	+21%	+$39.1M	0.64%	26
2017 Q2	$195M	Buy	3,608,924 +666,801	+23%	+$35.5M	0.56%	30
2017 Q1	$155M	Sell	2,942,123 -51,413	-2%	-$2.61M	0.44%	38
2016 Q4	$144M	Sell	2,993,536 -1,495,531	-33%	-$73.9M	0.43%	40
2016 Q3	$242M	Sell	4,489,067 -529,515	-11%	-$29M	0.7%	25
2016 Q2	$272M	Buy	5,018,582 +516,050	+11%	+$27.2M	0.79%	24
2016 Q1	$228M	Sell	4,502,532 -429,709	-9%	-$21.4M	0.71%	26
2015 Q4	$249M	Sell	4,932,241 -640,007	-11%	-$32.6M	0.79%	21
2015 Q3	$268M	Sell	5,572,248 -41,093	-0.7%	-$2.14M	0.87%	20
2015 Q2	$292M	Buy	5,613,341 +1,045,271	+23%	+$58.9M	0.88%	18
2015 Q1	$264M	Buy	4,568,070 +259,852	+6%	+$14.9M	0.8%	21
2014 Q4	$230M	Buy	4,308,218 +363,525	+9%	+$20.3M	0.71%	27
2014 Q3	$227M	Buy	3,944,693 +556,345	+16%	+$34.1M	0.73%	27
2014 Q2	$227M	Buy	3,388,348 +695,757	+26%	+$47.1M	0.71%	29
2014 Q1	$180M	Buy	2,692,591 +148,359	+6%	+$10M	0.6%	33
2013 Q4	$170M	Buy	2,544,232 +72,704	+3%	+$4.71M	0.59%	33
2013 Q3	$155M	Buy	2,471,528 +45,818	+2%	+$2.95M	0.6%	34
2013 Q2	$152M	Buy	+2,425,710	New	+$154M	0.6%	37

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Federated Hermes's GSK Position: Q1 2026 in Review

Federated Hermes reduced its GSK (GSK) stake by 94% in Q1 2026, selling an estimated $145M and leaving 169,014 shares worth $9.33M. The position accounts for 0.02% of the portfolio, ranked #658.

Federated Hermes first reported a position in GSK in Q2 2013 and has held it in 43 quarters since. The position peaked at $292M in Q2 2015. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Federated Hermes held 169,014 shares of GSK worth $9.33M as of Q1 2026.
Federated Hermes sold 2,674,401 GSK shares in Q1 2026, an estimated $145M.
GSK made up 0.02% of Federated Hermes's portfolio in Q1 2026, its #658 holding.
Federated Hermes first reported a position in GSK in Q2 2013 and has held it in 43 quarters since.
Federated Hermes's GSK position peaked at $292M in Q2 2015.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.